BIOMAT Database Logo BIOMAT Database Logo

Saralasin infusion in the recognition of renovascular hypertension. 1977

H M Wilson, and J P Wilson, and P E Slaton, and J H Foster, and G W Liddle, and J W Hollifield

Saralasin, an angiotensin II antagonist, was infused into 49 patients with renal artery stenosis, 10 patients with essential hypertension and normal renal arteriograms, and five patients with "low-renin essential hypertension." Renal venous renin and differential renal function studies were used to assess the functional significance of arterial stenoses. "Response" to saralasin, evidenced by a fall in blood pressure during infusion, occurred in no patients with "low renin" hypertension and in only 20% of patients with normal renal arteriograms. In contrast, saralasin "response" occurred in more than 80% of patients with renal artery stenosis and lateralizing functional studies and 100% of cases of "proven" renovascular hypertension (cure or improvement of hypertension after operative treatment). We suggest that saralasin infusion might be a valuable screening test for the recognition of renovascular hypertension.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D006977 Hypertension, Renal Persistent high BLOOD PRESSURE due to KIDNEY DISEASES, such as those involving the renal parenchyma, the renal vasculature, or tumors that secrete RENIN. Hypertensions, Renal,Renal Hypertension,Renal Hypertensions
D009392 Nephrectomy Excision of kidney. Heminephrectomy,Heminephrectomies,Nephrectomies
D012078 Renal Artery Obstruction Narrowing or occlusion of the RENAL ARTERY or arteries. It is due usually to ATHEROSCLEROSIS; FIBROMUSCULAR DYSPLASIA; THROMBOSIS; EMBOLISM, or external pressure. The reduced renal perfusion can lead to renovascular hypertension (HYPERTENSION, RENOVASCULAR). Renal Artery Stenosis,Obstruction, Renal Artery,Obstructions, Renal Artery,Renal Artery Obstructions,Renal Artery Stenoses,Stenoses, Renal Artery,Stenosis, Renal Artery
D012083 Renin A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19. Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D003937 Diagnosis, Differential Determination of which one of two or more diseases or conditions a patient is suffering from by systematically comparing and contrasting results of diagnostic measures. Diagnoses, Differential,Differential Diagnoses,Differential Diagnosis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D012504 Saralasin An octapeptide analog of angiotensin II (bovine) with amino acids 1 and 8 replaced with sarcosine and alanine, respectively. It is a highly specific competitive inhibitor of angiotensin II that is used in the diagnosis of HYPERTENSION. 1-Sar-8-Ala Angiotensin II,1-Sarcosine-8-Alanine Angiotensin II,(Sar(1),Ala(8))ANGII,(Sar1,Val5,Ala8)Angiotensin II,Angiotensin II, Sar(1)-Ala(8)-,Angiotensin II, Sarcosyl(1)-Alanine(8)-,Sar-Arg-Val-Tyr-Val-His-Pro-Ala,Saralasin Acetate,Saralasin Acetate, Anhydrous,Saralasin Acetate, Hydrated,1 Sar 8 Ala Angiotensin II,1 Sarcosine 8 Alanine Angiotensin II,Angiotensin II, 1-Sar-8-Ala,Angiotensin II, 1-Sarcosine-8-Alanine,Anhydrous Saralasin Acetate,Hydrated Saralasin Acetate

Related Publications

H M Wilson, and J P Wilson, and P E Slaton, and J H Foster, and G W Liddle, and J W Hollifield
Saralasin infusion in renovascular and essential hypertension.
January 1980, The Netherlands journal of medicine,
H M Wilson, and J P Wilson, and P E Slaton, and J H Foster, and G W Liddle, and J W Hollifield
Saralasin infusion in screening patients for renovascular hypertension.
March 1980, The American journal of cardiology,
H M Wilson, and J P Wilson, and P E Slaton, and J H Foster, and G W Liddle, and J W Hollifield
Saralasin infusion in renovascular hypertension: increased response rate in seated patients.
February 1980, Mayo Clinic proceedings,
H M Wilson, and J P Wilson, and P E Slaton, and J H Foster, and G W Liddle, and J W Hollifield
Saralasin for diagnosis of renovascular hypertension.
January 1982, The Medical letter on drugs and therapeutics,
H M Wilson, and J P Wilson, and P E Slaton, and J H Foster, and G W Liddle, and J W Hollifield
Negative saralasin response in correctable renovascular hypertension.
September 1978, The Journal of pediatrics,
H M Wilson, and J P Wilson, and P E Slaton, and J H Foster, and G W Liddle, and J W Hollifield
False-negative saralasin responses in renovascular hypertension.
April 1979, British journal of urology,
H M Wilson, and J P Wilson, and P E Slaton, and J H Foster, and G W Liddle, and J W Hollifield
Use of saralasin to detect renovascular hypertension in childhood.
November 1980, Urology,
H M Wilson, and J P Wilson, and P E Slaton, and J H Foster, and G W Liddle, and J W Hollifield
[Saralasin for renovascular or essential hypertension (author's transl)].
November 1978, Deutsche medizinische Wochenschrift (1946),
H M Wilson, and J P Wilson, and P E Slaton, and J H Foster, and G W Liddle, and J W Hollifield
Renal vein renin and saralasin testing in renovascular hypertension.
November 1978, American heart journal,
H M Wilson, and J P Wilson, and P E Slaton, and J H Foster, and G W Liddle, and J W Hollifield
[The Saralasin test in the diagnosis of renovascular hypertension. Personal experience].
January 1979, Minerva nefrologica,
Copied contents to your clipboard!